[(3-Pyridylalkyl)piperidylidene]benzocycloheptapyridine Derivatives as Dual Antagonists of PAF and Histamine
作者:Elena Carceller、Manuel Merlos、Marta Giral、Dolors Balsa、Carmen Almansa、Javier Bartroli、Julian Garcia-Rafanell、Javier Forn
DOI:10.1021/jm00043a009
日期:1994.8
A series of [(3-pyridylalkyl)piperidylidene]- and (nicotinoylpiperidylidene)benzocycloheptapyridine derivatives, Ia,b, were prepared and evaluated for PAF antagonist and H1 antihistamine activity. PAF antagonist activity was investigated by the in vitro PAF-induced platelet aggregation assay (PPA) and the in vivo PAF-induced hypotension test in rats (PH) and mortality test in mice (PM). For the evaluation
制备了一系列的[(3-吡啶基烷基)哌啶基]-和(烟酰基哌啶基)苯并环庚吡啶衍生物Ia,b,并评价了PAF拮抗剂和H1抗组胺活性。通过体外PAF诱导的血小板聚集测定(PPA)和体内PAF诱导的大鼠低血压测试(PH)和小鼠的死亡率测试(PM),研究了PAF拮抗剂的活性。为了评估H1抗组胺药的活性,在血压正常的大鼠中使用了体外组胺引起的豚鼠回肠试验(HC)收缩和体内组胺引起的低血压试验(HH)。使用活性过敏性休克试验在小鼠中评估了化合物的潜在抗过敏活性。这些化合物在结构上与氯雷他定(1)有关,是通过用取代的3-吡啶基甲基和烟酰基部分取代1的乙氧羰基而生成的。抗PAF和H1抗组胺活性均显示出对吡啶环中取代基的确切性质和位置的高度依赖性。结合有(5-甲基-3-吡啶基)甲基的最佳结构19(UR-12592)表现出独特的双重活性,可抑制两种PAF诱导的作用(PPA,IC50 = 3.7 microM; PH,ID50